首页 | 本学科首页   官方微博 | 高级检索  
检索        


Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study
Authors:ZHANG Qi  ZHANG Rui-yan  QIU Jian-ping  JIN Hui-gen  ZHANG Jun-feng  WANG Xiao-long  JIANG Li  LIAO Min-lei  HU Jian  DING Feng-hua  ZHANG Jian-sheng  SHEN Wei-feng
Institution:[1]Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China [2]Department Of Cardiology, GonghHospital of shanghai Pudong District, Shanghai 200135, China [3]Department of Cardiology, Center Hospital of Shanghai Putuo District, Shanghai 200062, China [4]Department of Cardiology, No. 3 People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China [5]Department of Cardiology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201900, China [6]Department of Cardiology, Center Hospital of Shanghai Changning District, Shanghai 200336, China [7]Department of Cardiology, Wusong Hospital, Shanghai 201900, China
Abstract:Background Current guidelines support primary percutaneous coronary intervention (primary PCI) as the first treatment of choice (as opposed to thrombolytic therapy) for patients with acute ST-segment elevation myocardial infarction (STEMI) especially when delivered within 12 hours of symptom onset. We aimed to evaluate the impact of different clinical pathways on reduction of reperfusion delay and subsequent improvement in outcomes in patients with STEMI.Methods From November 2005 to November 2007, 546 consecutive patients with definite STEMI, who upon arrival at the emergency room were triaged to undergo primary PCI, were included. Of them, 271 patients were brought directly to catheterization laboratory (rapid group), and 275 patients were admitted to the coronary care unit (CCU) or cardiac ward first, and then transferred to the catheterization laboratory (non-rapid group). Primary endpoint was door-to-balloon (D28) time, and secondary endpoints included infarct size assessed by peak CK-MB level and rates of major cardiac adverse events (MACE) including death, reinfarction, or target-vessel revascularization during hospitalization and at 30-day clinical follow-up.Results Baseline clinical characteristics, angiographic features and procedural success rates were comparable between the two groups, except that more patients received glycoprotein Ⅱb/Ⅲa receptor inhibitors before angiography (84.0% and 77.1, P=0.042) and had TIMI 3 flow in the culprit vessel at initial angiogram (17.1% and 9.2%, P=0.007) in the non-rapid group. The D2B time was shortened ((108±44) minutes and (138±31) minutes, P <0.0001), and number of patients with D2B time <90 minutes was greater (22.6% and 10.9%, P <0.0001) in the rapid group. The advantages associated with rapid intra-hospital transfer were enhanced if the patients presented to the hospital at regular hours. Peak CK-MB level was significantly reduced in the rapid group. In-hospital mortality (4.1% and 5.8%) and cumulative MACE rate (7.0% and 9.8%) did not significantly differ between rapid and non-rapid groups. At 30 days, cumulative death-and MACE-free survival rates were improved in the rapid group (94.5% and 89.5%, P=0.035; 90.1% and 84.0%, P=0.034, respectively).Conclusions Clinical pathway with bypass of CCU/cardiac ward admission was associated with rapid reperfusion, smaller infarct size, and improved short-term survival for patients with STEMI undergoing primary PCI. In the future, it is essential to reduce the time delay for patients presenting at off-hours.
Keywords:myocardial infarction  angioplasty  stents  prognosis  critical pathway
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息
点击此处可从《中华医学杂志(英文版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号